Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials.

Paluri RK, Sonpavde G, Morgan C, Rojymon J, Mar AH, Gangaraju R.

Oncol Rev. 2019 Nov 25;13(2):455. doi: 10.4081/oncol.2019.455. eCollection 2019 Jul 22.

2.

Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions.

Fayne RA, Macedo FI, Rodgers SE, Möller MG.

Oncol Rev. 2019 Nov 28;13(2):433. doi: 10.4081/oncol.2019.433. eCollection 2019 Jul 22.

3.
4.

Potential effect of probiotics in the treatment of breast cancer.

Mendoza L.

Oncol Rev. 2019 Sep 27;13(2):422. doi: 10.4081/oncol.2019.422. eCollection 2019 Jul 22.

5.

Therapeutic options for ampullary carcinomas. A review.

Regalla DKR, Jacob R, Manne A, Paluri RK.

Oncol Rev. 2019 Sep 10;13(2):440. doi: 10.4081/oncol.2019.440. eCollection 2019 Jul 22.

6.

Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia.

Alsagaby SA.

Oncol Rev. 2019 Sep 10;13(2):435. doi: 10.4081/oncol.2019.435. eCollection 2019 Jul 22.

7.

Recent trends in predictive biomarkers for determining malignant potential of oral potentially malignant disorders.

Sarode GS, Sarode SC, Maniyar N, Sharma N, Yerwadekar S, Patil S.

Oncol Rev. 2019 Sep 10;13(2):424. doi: 10.4081/oncol.2019.424. eCollection 2019 Jul 22.

8.

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy.

Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, Camp ER.

Oncol Rev. 2019 Aug 1;13(2):430. doi: 10.4081/oncol.2019.430. eCollection 2019 Jul 22.

9.

CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Mohammed AA, Rashied H, Elsayed FM.

Oncol Rev. 2019 Jul 29;13(2):416. doi: 10.4081/oncol.2019.416. eCollection 2019 Jul 22.

10.

Epigenetic modification in the expression of p73 p73 - epigenetic target for anticancer therapy.

Naseer F, Saleem M.

Oncol Rev. 2019 Jul 24;13(2):421. doi: 10.4081/oncol.2019.421. eCollection 2019 Jul 22.

11.

Current promising treatment strategy for glioblastoma multiform: A review.

Bahadur S, Sahu AK, Baghel P, Saha S.

Oncol Rev. 2019 Jul 25;13(2):417. doi: 10.4081/oncol.2019.417. eCollection 2019 Jul 22.

12.

Prognostic significance of mutated genes in megakaryocytic disorders.

Asnafi AA, Mohammadi MB, Rezaeeyan H, Davari N, Saki N.

Oncol Rev. 2019 Jul 22;13(2):408. doi: 10.4081/oncol.2019.408. eCollection 2019 Jul 22.

13.

MCT4 has a potential to be used as a prognostic biomarker - a systematic review and meta-analysis.

Javaeed A, Ghauri SK.

Oncol Rev. 2019 Jul 22;13(2):403. doi: 10.4081/oncol.2019.403. eCollection 2019 Jul 22.

14.

Thrombocytopenia in solid tumors: Prognostic significance.

Ghanavat M, Ebrahimi M, Rafieemehr H, Maniati M, Behzad MM, Shahrabi S.

Oncol Rev. 2019 May 14;13(1):413. doi: 10.4081/oncol.2019.413. eCollection 2019 Jan 14.

15.

Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment.

Marmelo FC, Sá CFR.

Oncol Rev. 2019 Feb 1;13(1):383. doi: 10.4081/oncol.2019.383. eCollection 2019 Jan 14.

16.

Prospects for repurposing CNS drugs for cancer treatment.

Abdelaleem M, Ezzat H, Osama M, Megahed A, Alaa W, Gaber A, Shafei A, Refaat A.

Oncol Rev. 2019 Apr 17;13(1):411. doi: 10.4081/oncol.2019.411. eCollection 2019 Jan 14.

17.

Advances in pancreatic cancer biomarkers.

Hasan S, Jacob R, Manne U, Paluri R.

Oncol Rev. 2019 Feb 1;13(1):410. doi: 10.4081/oncol.2019.410. eCollection 2019 Jan 14.

18.

A comprehensive overview of mitochondrial DNA 4977-bp deletion in cancer studies.

Yusoff AAM, Abdullah WSW, Khair SZNM, Radzak SMA.

Oncol Rev. 2019 Apr 16;13(1):409. doi: 10.4081/oncol.2019.409. eCollection 2019 Jan 14.

19.

Adherence to oral pharmacological treatment in cancer patients: Systematic review.

Claros MP, Messa CVM, García-Perdomo HA.

Oncol Rev. 2019 Apr 16;13(1):402. doi: 10.4081/oncol.2019.402. eCollection 2019 Jan 14.

20.

Prognostic significance of aberrant CD5 expression in B-cell leukemia.

Jaseb K, Purrahman D, Shahrabi S, Ghanavat M, Rezaeean H, Saki N.

Oncol Rev. 2019 Apr 18;13(1):400. doi: 10.4081/oncol.2019.400. eCollection 2019 Jan 14.

Supplemental Content

Loading ...
Support Center